Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Chief Med & Dev Officer | October 01, 2026 | October 05, 2026 |
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | September 14, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,529 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 1,047 · Balance 43,529 F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Corbus Pharmaceuticals Holdings, Inc.
Report date September 14, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 9,383 |
Reported balance
After 2026-09-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-14 · Sale · Disposed 2,000 · Balance 9,383 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 to $7.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: This amount includes 3,800 unvested RSUs subject to each grant's vesting schedule as previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 to $7.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This amount includes 3,800 unvested RSUs subject to each grant's vesting schedule as previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:11 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 1,047 | $3.94 | $4,125.18 |
DisclosureSEC source: 0001193125-26-414123 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,529 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 20:59 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | SaleCommon Stock, par value $0.0001 per share | 2,000 | $7.84 | $15,683.00 |
DisclosureSEC source: 0001193125-26-392093 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,383 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 to $7.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: This amount includes 3,800 unvested RSUs subject to each grant's vesting schedule as previously reported. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 1,047 | $7.80 | $8,166.60 |
DisclosureSEC source: 0001193125-26-296502 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,576 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:05 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 12,300 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001193125-26-234850 · ownership.xml · derivative · entry 2 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2026-05-19 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:05 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234850 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,383 F1 · shares: On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. Read SEC document |
| April 01, 2026 Filed May 5, 2026 23:05 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 1,047 | $9.03 | $9,454.41 |
DisclosureSEC source: 0001193125-26-207041 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,623 F1 · shares: Represents shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:56 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001193125-26-104369 · ownership.xml · derivative · entry 2 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2036-03-09 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:56 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantCommon Stock | 46,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-104369 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,670 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:37 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 357,177 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-111997 · ownership.xml · derivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,177 Underlying: Common Stock · 357,177 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 16,000 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0000950170-25-080312 · ownership.xml · derivative · entry 2 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-30 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080312 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,583 F1 · shares: On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:28 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068013 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:54 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 2,783 | $0.00 Strike: $45.92 | $0.00 |
DisclosureSEC source: 0001209191-24-005671 · doc4.xml · derivative · entry 1 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 Underlying: Common Stock · 2,783 shares Expires 2034-05-16 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:20 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001209191-23-031448 · doc4.xml · derivative · entry 1 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2033-05-18 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 15:19 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 5,307 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001209191-23-016575 · doc4.xml · derivative · entry 1 Ben Yong · CIK 0001967669 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,307 Underlying: Common Stock · 5,307 shares Expires 2023-03-06 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.